Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | T3P-Y058-739 |
| Synonyms | |
| Therapy Description |
T3P-Y058-739 is an attenuated bacterial strain carrying undisclosed type 1 Interferon and Toll-like receptor payloads, which potentially increases anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| T3P-Y058-739 | T3PY058739|T3P Y058739|T3PY 058739 | T3P-Y058-739 is an attenuated bacterial strain carrying undisclosed type 1 Interferon and Toll-like receptor payloads, which potentially increases anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05120596 | Phase Ib/II | Pembrolizumab + T3P-Y058-739 T3P-Y058-739 | First in Human Study of T3P-Y058-739 (T3P) | Recruiting | GBR | ESP | CHE | 0 |